Edward B. Garon
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies
Most-Cited Works
- → Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer(2015)7,863 cited
- → Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial(2015)6,477 cited
- → Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer(2018)6,458 cited
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs(2014)1,725 cited
- → Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial(2014)1,290 cited
- → Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy(2017)1,147 cited
- → Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer(2020)1,132 cited
- → Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial(2017)1,074 cited
- → Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer(2020)977 cited